Sippican Capital Advisors Apellis Pharmaceuticals, Inc. Transaction History
Sippican Capital Advisors
- $130 Million
- Q3 2024
A detailed history of Sippican Capital Advisors transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Sippican Capital Advisors holds 30,313 shares of APLS stock, worth $999,116. This represents 0.67% of its overall portfolio holdings.
Number of Shares
30,313
Previous 23,178
30.78%
Holding current value
$999,116
Previous $889,000
1.69%
% of portfolio
0.67%
Previous 0.76%
Shares
9 transactions
Others Institutions Holding APLS
# of Institutions
308Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$513 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$392 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$366 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$324 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$191 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.62B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...